Skip to main content

Table 1 Composition of the experimental M. hyopneumoniae bacterins and their route of administration

From: Efficacy of three innovative bacterin vaccines against experimental infection with Mycoplasma hyopneumoniae

Vaccine formulation

Dose (mL)

Delivery system

Immune-stimulators (µg/dose)

Antigen dose (CCU/dose)

Administration route (primo and booster)

Lipo_DDA:TDB

2

DDA liposomes

TDB (500)

109

IM

PLGA_TLR

PLGA micro-particles (combined to ethylaminoethyl-dextran)

Pam3Cys-SK4/CpG ODN SL03/resiquimod (80/80/80)

SWE_TLR

Squalene-in-water emulsion

  1. CCU: colour changing units, IM: intramuscular, PLGA: poly(lactic-co-glycolic acid), DDA: dimethyl dioctadecylammonium, TDB: trehalose 6,6′-dibehenate.